A Phase 4 interventional study of Interferon beta-1a in Multiple Sclerosis, Relapsing, Remitting, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-27.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 12th largest by enrollment, is one of 4 that started in 2005, is one of 13 in phase 4, and was the 15th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 80 across the 21 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 8 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 40 studies in Multiple Sclerosis, Relapsing-Remitting by Merck KGaA, Darmstadt, Germany, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2005, is one of 7 in phase 4, and was the 28th registered.
Merck KGaA, Darmstadt, Germany’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 40 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is planned to evaluate emotional disorders during treatment by interferon (IFN) beta in relapsing remitting multiple sclerosis (RRMS) subjects. This is an open-label exploratory study with no change of therapeutic behavior but with standardized neuropsychologic follow-up.
This study is planned to evaluate emotional disorders during treatment by IFN beta in RRMS subjects. This is an open-label, prospective, interventional, multicentric study with no change of therapeutic behavior but with standardized neuropsychologic follow-up. Subjects will undergo 13 evaluations (categorical and dimensional evaluations), 3 evaluations will be performed before the treatment (Baseline, Day 7 and 15) and 10 evaluations after the treatment (Month 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Also known as: Rebif
Change From Baseline in Emotional Dyscontrol Sub-score of the Depressive Mood Scale (Echelle d'Humeur Depressive [EHD]) Scale at Month 12
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
Time frame: Baseline and Month 12
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
Time frame: Baseline and Month 18
Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
Time frame: Baseline and Month 24
Change From Baseline in Emotional Abrasion Sub-score of the EHD Scale at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional abrasion sub-score is the sum of items 3, 6, 7, and 8. The total possible score range from 1 (not at all) to 16 (very much), where 16 corresponds to worst state. (Radat F et al., 2007)
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Change From Baseline in State-trait Anxiety Inventory (STAI State) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
STAI state scale is an auto-evaluation scale for anxiety. This scale includes 20 items that allow quantifying feeling of apprehension, tension, nervousness and worry that the participant feels at the time of the completion of the questionnaire. The 20 items are graded from 1 (no) to 4 (yes), where 'yes' corresponds to the best state for items 1, 2, 5, 8, 10, 11, 15, 16, 19, 20 (scoring was reversed before calculation of total score); and to the worst state for items 3, 4, 6, 7, 9, 12, 13, 14, 17, 18. The total score ranged from 1 (best state) to 80 (worst state). (Spielberger CD et al., 1983)
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Change From Baseline in Center for Epidemiologic Studies Depression (CES-D) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
CES-D is an auto-questionnaire including 20 items to screen for depressive feelings and behaviour. The 20 items of this scale are graded from 0 (never) to 3 (always), where 3 corresponds to the most severe state with the exception of items 4, 8, 12 and 16 (scoring was reversed before the calculation of the total score). Total score ranged from 0 (never) to 60 (always), where 60 corresponds to most severe state. (Radloff LS, 1977)
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Change From Baseline in Center for State-trait Anger Expression Inventory 2 (STAXI-state) Score at Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
STAXI-state scale measures the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). In this study only 1 of the original 6 scales was used, the state anger scale, which measures the intensity of anger at a given moment as emotional state. This scale consists of 15 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The total score range from 1 (not at all) to 60 (very much), where 60 corresponds to the worst state. (Spielberger CD, 1996)
Time frame: Baseline, Months 1, 2, 3, 4, 5, 6, 9, 12, 18 and 24
Change From Baseline in Fatigue Score at Months 1, 2, 3, 6, 12 and 24
Fatigue scale was derived from the United Kingdom Neurological Disability Scale (UKNDS), and evaluates fatigue according to the participant's subjective impression and the functional disability that it causes. 'Yes' or 'No' answers result in a score that ranges from 0 to 5, where a score 5 shows worse state. (Sharrack B et al., 1999)
Time frame: Baseline, Months 1, 2, 3, 6, 12, and 24
| Milestone | Interferon-beta |
|---|---|
| Started | 79 |
| Treated | 76 |
| Completed | 60 |
| Not completed | 19 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Participant wrongly included in trial | 1 |
| Withdrew: Randomized, not treated | 3 |
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 70) | 12.7 ± 4.4 |
| Change at Month 12 (n= 57) | -0.5 ± 4.2 |
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
| units on a scale | Interferon-beta |
|---|---|
| Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 18 | -0.6 ± 4.6 |
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional dyscontrol sub-score is the sum of items 1, 2, 4, 5, 9, 10, and 11. The total possible score range from 1 (not at all) to 28 (very much), where 28 corresponds to worst state. (Radat F et al., 2007)
| units on a scale | Interferon-beta |
|---|---|
| Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale at Month 24 | -0.1 ± 5.2 |
EHD scale is a tool to assess the depressive mood dimensions 'lack of emotional control' (emotional dyscontrol) and 'blunted effect' which comprises of 11 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The emotional abrasion sub-score is the sum of items 3, 6, 7, and 8. The total possible score range from 1 (not at all) to 16 (very much), where 16 corresponds to worst state. (Radat F et al., 2007)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 70) | 5.6 ± 1.6 |
| Change at Month 1 (n= 64) | 0.3 ± 1.6 |
| Change at Month 2 (n= 62) | -0.1 ± 1.7 |
| Change at Month 3 (n= 64) | -0.0 ± 1.6 |
| Change at Month 4 (n= 59) | -0.0 ± 1.8 |
| Change at Month 5 (n= 58) | -0.2 ± 1.5 |
| Change at Month 6 (n= 56) | -0.3 ± 1.8 |
| Change at Month 9 (n= 58) | -0.1 ± 1.8 |
| Change at Month 12 (n= 57) | -0.0 ± 2.3 |
| Change at Month 18 (n= 61) | -0.3 ± 1.9 |
| Change at Month 24 (n= 63) | -0.3 ± 1.7 |
STAI state scale is an auto-evaluation scale for anxiety. This scale includes 20 items that allow quantifying feeling of apprehension, tension, nervousness and worry that the participant feels at the time of the completion of the questionnaire. The 20 items are graded from 1 (no) to 4 (yes), where 'yes' corresponds to the best state for items 1, 2, 5, 8, 10, 11, 15, 16, 19, 20 (scoring was reversed before calculation of total score); and to the worst state for items 3, 4, 6, 7, 9, 12, 13, 14, 17, 18. The total score ranged from 1 (best state) to 80 (worst state). (Spielberger CD et al., 1983)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 70) | 35.9 ± 11.8 |
| Change at Month 1 (n= 65) | 0.8 ± 10.5 |
| Change at Month 2 (n= 62) | 0.3 ± 12.3 |
| Change at Month 3 (n= 64) | -1.7 ± 11.5 |
| Change at Month 4 (n= 59) | -1.5 ± 11.0 |
| Change at Month 5 (n= 58) | -0.8 ± 9.2 |
| Change at Month 6 (n= 55) | -1.4 ± 11.5 |
| Change at Month 9 (n= 58) | -0.2 ± 10.5 |
| Change at Month 12 (n= 57) | -0.3 ± 12.7 |
| Change at Month 18 (n= 61) | -1.2 ± 11.2 |
| Change at Month 24 (n= 63) | -1.4 ± 13.1 |
CES-D is an auto-questionnaire including 20 items to screen for depressive feelings and behaviour. The 20 items of this scale are graded from 0 (never) to 3 (always), where 3 corresponds to the most severe state with the exception of items 4, 8, 12 and 16 (scoring was reversed before the calculation of the total score). Total score ranged from 0 (never) to 60 (always), where 60 corresponds to most severe state. (Radloff LS, 1977)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 70) | 13.5 ± 11.1 |
| Change at Month 1 (n= 65) | 1.0 ± 8.6 |
| Change at Month 2 (n= 62) | 1.5 ± 10.6 |
| Change at Month 3 (n= 64) | -0.5 ± 9.9 |
| Change at Month 4 (n= 58) | -1.0 ± 9.8 |
| Change at Month 5 (n= 58) | -1.1 ± 8.6 |
| Change at Month 6 (n= 56) | 0.9 ± 9.2 |
| Change at Month 9 (n= 58) | 0.9 ± 10.7 |
| Change at Month 12 (n= 57) | 1.6 ± 10.8 |
| Change at Month 18 (n= 61) | -0.2 ± 9.0 |
| Change at Month 24 (n= 63) | 0.1 ± 10.1 |
STAXI-state scale measures the intensity of anger as an emotional state (state anger) and the disposition to experience angry feelings as a personality trait (trait anger). In this study only 1 of the original 6 scales was used, the state anger scale, which measures the intensity of anger at a given moment as emotional state. This scale consists of 15 items graded in 4 degrees from 1 (not at all) to 4 (very much), where 4 corresponds to the worst state. The total score range from 1 (not at all) to 60 (very much), where 60 corresponds to the worst state. (Spielberger CD, 1996)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 70) | 16.8 ± 4.1 |
| Change at Month 1 (n= 65) | 0.0 ± 4.2 |
| Change at Month 2 (n= 62) | 1.0 ± 5.3 |
| Change at Month 3 (n= 64) | -0.0 ± 5.3 |
| Change at Month 4 (n= 59) | -0.3 ± 4.7 |
| Change at Month 5 (n= 58) | -0.0 ± 2.9 |
| Change at Month 6 (n= 56) | 1.1 ± 7.6 |
| Change at Month 9 (n= 58) | 1.1 ± 5.9 |
| Change at Month 12 (n= 57) | 0.9 ± 5.7 |
| Change at Month 18 (n= 61) | 0.8 ± 5.4 |
| Change at Month 24 (n= 63) | 1.0 ± 5.5 |
Fatigue scale was derived from the United Kingdom Neurological Disability Scale (UKNDS), and evaluates fatigue according to the participant's subjective impression and the functional disability that it causes. 'Yes' or 'No' answers result in a score that ranges from 0 to 5, where a score 5 shows worse state. (Sharrack B et al., 1999)
| units on a scale | Interferon-beta |
|---|---|
| Baseline (n= 62) | 2.1 ± 1.7 |
| Change at Month 1 (n= 58) | 0.5 ± 1.6 |
| Change at Month 2 (n= 55) | 0.4 ± 1.5 |
| Change at Month 3 (n= 56) | 0.2 ± 1.8 |
| Change at Month 6 (n= 50) | 0.4 ± 1.8 |
| Change at Month 12 (n= 49) | 0.1 ± 1.8 |
| Change at Month 24 (n= 56) | -0.1 ± 2.1 |
Collected over Baseline to Month 24. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Interferon-beta | — | 9/76 (11.8%) | 62/76 (81.6%) |
| Event | Interferon-beta |
|---|---|
| DepressionPsychiatric disorders | 3/76 |
| Lung DisorderRespiratory, thoracic and mediastinal disorders | 1/76 |
| Sudden Hearing LossEar and labyrinth disorders | 1/76 |
| AbortionPregnancy, puerperium and perinatal conditions | 1/76 |
| AnxietyPsychiatric disorders | 1/76 |
| HeadacheNervous system disorders | 1/76 |
| Drug DependencePsychiatric disorders | 1/76 |
| AggressivityPsychiatric disorders | 1/76 |
| Suicide AttemptPsychiatric disorders | 1/76 |
| Neck InjuryInjury, poisoning and procedural complications | 1/76 |
| Event | Interferon-beta |
|---|---|
| Multiple Sclerosis RelapseNervous system disorders | 40/76 |
| Influenza Like IllnessGeneral disorders | 18/76 |
| FatigueGeneral disorders | 11/76 |
| Injection Site PainGeneral disorders | 7/76 |
| DepressionPsychiatric disorders | 6/76 |
| Injection Site ErythemaGeneral disorders | 5/76 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 4/76 |
| Cytolytic HepatitisHepatobiliary disorders | 3/76 |
| HeadacheNervous system disorders | 2/76 |
| MigraineNervous system disorders | 2/76 |
| Age, Continuous(years) | Interferon-beta |
|---|---|
| Mean | 37.0 ± 11.5 |
| Sex: Female, Male(Participants) | Interferon-beta |
|---|---|
| Female | 56 |
| Male | 14 |
No study locations are listed for this record.
The record gives a start of Jan 2005, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Multiple Sclerosis, Relapsing-Remitting →
Merck KGaA, Darmstadt, Germany →